FDA grants relugolix priority review for advanced prostate cancer

June 22, 2020

The FDA has granted a priority review to relugolix for the treatment of patients with advanced prostate cancer

Personalized cancer vaccine combo induces clinical benefit in advanced solid tumors

June 22, 2020

The combination of the personalized cancer vaccine RO719845 and the PD-L1 inhibitor atezolizumab showed strong clinical activity across solid tumors, including bladder cancer and renal cell carcinoma.

Atezolizumab shows similar efficacy in upper tract urothelial carcinoma and standard bladder cancer

June 19, 2020

Median overall survival is the same for both malignancies, study results show.

Dr. Nguyen discusses robotic surgery in pediatric patients

June 19, 2020

Michael T. Nguyen, MD, discusses the use of robotic surgery in pediatric patients as well as how his practice has been affected by the COVID-19 pandemic.

Ipatasertib plus abiraterone and prednisone delays progression in mCRPC with PTEN loss

June 19, 2020

Phase 3 data showed that the addition of the AKT inhibitor ipatasertib to standard therapy boosted radiographic progression-free survival in patients with advanced castration-resistant prostate cancer whose tumors had PTEN loss.

Circulating tumor cells are strong early signal of prostate cancer recurrence

June 18, 2020

Following radical prostatectomy, circulating tumor cells may indicate an increased risk of recurrence earlier than a PSA rise.

Pandemic exacts economic toll on urology practices

June 18, 2020

As practices reboot, urologists consider leaner staffs and operations.

Biomarker combo forecasts improved survival with anti–PD-1/L1 agents in bladder cancer

June 18, 2020

The dual biomarker of ARID1A mutations and CXCL13 expression was associated with improved overall survival in patients with advanced urothelial carcinoma.

Immune checkpoint inhibitors effective in variant urothelial carcinoma

June 17, 2020

Anti–PD-1/PD-L1 agents were associated with similar efficacy across pure and variant histologies in patients with advanced urothelial carcinoma, with the exception of those with a neuroendocrine variant.